Sign in
TGTX Stock Price, Chart, Stats & News
TG Therapeutics, Inc.
Save
8.26B
Market cap
18.54x
Current P/E
41.84x
Forward P/E
TGTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 83.64% |
Operating margin | 20.01% |
Pretax margin | 17.43% |
Net margin | 72.56% |
Effective tax rate | -316.41% |
ROA | 42.06% |
ROE | 101.12% |
D/E | 0.40x |
Interest coverage ratio | 4.61x |
TGTX valuation
P/E | 18.54x |
P/S | 8.23x |
P/B | 7.00x |
P/CF | -183.23x |
P/FCF | -202.92x |
P/OCF | -183.23x |
PEG | 0.10x |
EV multiple | 36.38x |
About
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders.
Similar securities
Based on sector and market capitalization
Report issue